These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34273922)

  • 1. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
    Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
    Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
    Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
    Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
    Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.
    Cai L; Tao T; Li H; Zhang Z; Zhang L; Li X
    J Glob Health; 2022 Dec; 12():11016. PubMed ID: 36527382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.
    Yang Y; Zhang Y; Wagner AK; Li H; Shi L; Guan X
    J Glob Health; 2023 Aug; 13():04083. PubMed ID: 37566690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis.
    Li C; Zhu J; Shan L; Zhou Y; Liu G; Zhu H; Wu Q; Cui Y; Kang Z
    BMC Health Serv Res; 2024 Jan; 24(1):90. PubMed ID: 38233857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
    Liu Y; Yi H; Fang K; Bao Y; Li X
    Front Public Health; 2022; 10():942638. PubMed ID: 35937254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
    Huang C; Ung COL; Wushouer H; Bai L; Huang T; Li X; Guan X; Shi L
    Health Res Policy Syst; 2022 Jan; 20(1):3. PubMed ID: 34980159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
    Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.
    Luo Z; Gyawali B; Han S; Shi L; Guan X; Wagner AK
    Semin Oncol; 2021 Apr; 48(2):141-144. PubMed ID: 33875231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
    Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
    BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.
    Zhu H; Zhu J; Zhou Y; Shan L; Li C; Cui Y; Kang Z; Jiao M; Liu H; Gao L; Wu Q; Hao Y
    Front Public Health; 2022; 10():921093. PubMed ID: 35844892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
    Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
    Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.
    Wang X; Huang H; Sun Y; Zhu Z; Jiang B; Yang L
    BMJ Open; 2023 Jul; 13(7):e064199. PubMed ID: 37407064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study.
    Gao X; Yu M; Sun Y; Zhang T; Li X; Zhang L; Wang C
    Risk Manag Healthc Policy; 2024; 17():2201-2208. PubMed ID: 39309121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis.
    Qin Z; He M; Shen H; Liu S; Xu S; Chen L
    Front Public Health; 2024; 12():1381786. PubMed ID: 38903594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation.
    Wu D; Xie J; Dai H; Fang W
    BMC Health Serv Res; 2022 Apr; 22(1):431. PubMed ID: 35365136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
    Rong X; Yin J; Duan S; Sun Q; Babar ZU
    BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Price negotiation and pricing of anticancer drugs in China: An observational study.
    Zhou J; Lan T; Lu H; Pan J
    PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.
    Ding Y; Zheng C; Wei X; Zhang Q; Sun Q
    BMC Public Health; 2022 Dec; 22(1):2363. PubMed ID: 36527037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.